M. Fey

发表

Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.

R. Gelber, A. Goldhirsch, J. Collins, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices.

M. Fey, S. Aebi, D. Zahnd, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1

B. Torbett, M. Tschan, M. Fey, 2006, Oncogene.

Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells.

M. Fey, A. Tobler, H. Koeffler, 1995, The Journal of clinical investigation.

The cyclin‐dependent kinase inhibitors p18INK4c and p19INK4d are highly expressed in CD34+ progenitor and acute myeloid leukaemic cells but not in normal differentiated myeloid cells

M. Tschan, M. Fey, J. Cajot, 1999, British journal of haematology.

Comparative detection and quantitation of human CDK inhibitor mRNA expression of p15INK4B, p16INK4A, p16β, p18INK4C, p19INK4D, p21WAF1, p27KIP1 and p57KIP2 by RT‐PCR using a polycompetitive internal standard

M. Fey, A. Tobler, J. Schwaller, 1997, British journal of haematology.

Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils

S. Lowe, M. Fey, H. Simon, 2006, Oncogene.

Structural integrity of the cyclin‐dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias

Carl W. Miller, M. Fey, A. Tobler, 1995, British journal of haematology.

The impact of chip technology on cancer medicine.

M. Fey, M F Fey, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression

M. Tschan, M. Fey, M. Borner, 1998, Oncogene.

The Tumor Suppressor Gene Hypermethylated in Cancer 1 Is Transcriptionally Regulated by E2F1

M. Tschan, D. Leprince, K. Helin, 2009, Molecular Cancer Research.

The Tumor Suppressor Gene Hypermethylated in Cancer 1 Is Transcriptionally Regulated by E 2 F 1

M. Tschan, D. Leprince, K. Helin, 2009 .

Clinical Cancer Research Collaborative Group (SAKK) and for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for

E. Vellenga, M. Fey, A. Gratwohl, 2011 .

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.

E. Vellenga, M. Fey, A. Gratwohl, 2011, Blood.

Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.

M. Tschan, M. Fey, M. Borner, 1998, Oncogene.

Coagulation Markers Predict Survival in Cancer Patients

M. Fey, A. Haeberli, J. Beer, 2002, Thrombosis and Haemostasis.

NDRG1/2 expression is inhibited in primary acute myeloid leukemia.

M. Tschan, M. Fey, A. Tobler, 2010, Leukemia research.

The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).

R. Herrmann, A. Goldhirsch, M. Castiglione, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: first results of International Breast Cancer Study Group Trial 13–93

A. Coates, J. Lindtner, M. Fey, 2004 .

Abnormal p53 expression is rare in clinically localized human prostate cancer: Comparison between immunohistochemical and molecular detection of p53 mutations

U. Studer, M. Fey, G. Thalmann, 1997, The Prostate.

Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study

F. Terrier, A. Goldhirsch, M. Fey, 2005, Journal of Cancer Research and Clinical Oncology.

Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).

M. Fey, A. Tobler, A. Tichelli, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Alternative Splicing of the Human Cyclin D-binding Myb-like Protein (hDMP1) Yields a Truncated Protein Isoform That Alters Macrophage Differentiation Patterns*

B. Torbett, M. Tschan, M. Fey, 2003, Journal of Biological Chemistry.

HIV-testing and Newly-diagnosed Malignant Lymphomas. The SAKK 96/90 Registration Study

F. Cavalli, R. Stahel, J. Torhorst, 2003, Leukemia & lymphoma.

T-cell-rich B-cell non-Hodgkin's lymphoma mimicking Hodgkin's disease.

M. Fey, S. Cogliatti, J. Laissue, 1999, Leukemia & lymphoma.

Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?

F. Cavalli, A. Goldhirsch, C. Hürny, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in metastatic breast cancer.

M. Fey, K. Brunner, R. Sonntag, 1981, Cancer clinical trials.

Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)

F. Cavalli, A. Goldhirsch, M. Castiglione, 1997, European journal of cancer.

The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry.

P. Jüni, M. Fey, M. Egger, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Transcriptional regulation of MIR29B by PU.1 (SPI1) and MYC during neutrophil differentiation of acute promyelocytic leukaemia cells

B. Torbett, M. Tschan, M. Fey, 2012, British journal of haematology.

Inflammation-associated Cell Cycle–independent Block of Apoptosis by Survivin in Terminally Differentiated Neutrophils

M. Fey, H. Simon, S. Yousefi, 2004, The Journal of experimental medicine.

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.

F. Cavalli, A. Goldhirsch, B. Thürlimann, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction of Bim limits cytokine-mediated prolonged survival of neutrophils

M. Fey, H. Simon, E. Schneider, 2009, Cell Death and Differentiation.

Interleukin-8 Expression by Fetal and Neonatal Pulmonary Cells in Hyaline Membrane Disease and Amniotic Infection

M. Fey, A. Tobler, T. Stallmach, 2000, Pediatric Research.

Autophagy is required for self-renewal and differentiation of adult human stem cells

M. Fey, H. Simon, S. Yousefi, 2011, Cell Research.

The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin.

J. Rowley, A. Hagemeijer, M. Fey, 2004, Proceedings of the National Academy of Sciences of the United States of America.

The costs of care in haematological cancers: Health economic issues

M. Fey, 2017, Hematological oncology.

Disparate expression of the PTEN gene: a novel finding in B‐cell chronic lymphocytic leukaemia (B‐CLL)

M. Fey, B. Hügli, A. Tobler, 2003, British journal of haematology.

Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts.

M. Fey, B. Dewald, M. Baggiolini, 1992, Blood.

Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation

T. Fehm, M. Fey, M. von Wolff, 2017, Archives of Gynecology and Obstetrics.

Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

Dirk Rades, Guido Schwarzer, Jerome Seidenfeld, 2009, The Cochrane database of systematic reviews.

Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

J. Forbes, R. Gelber, A. Goldhirsch, 2004, British Journal of Cancer.

The Notch pathway in ovarian carcinomas and adenomas

M. Fey, S. Aebi, O. Hopfer, 2005, British Journal of Cancer.

Original article Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma

M. Fey, M. Borner, G. Zulian, 2005 .

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

C. Hürny, B. Thürlimann, M. Fey, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Inhibition of GATE-16 attenuates ATRA-induced neutrophil differentiation of APL cells and interferes with autophagosome formation.

B. Torbett, M. Tschan, M. Fey, 2013, Biochemical and biophysical research communications.

The death‐associated protein kinase 2 is up‐regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells

B. Torbett, M. Tschan, M. Fey, 2007, Journal of leukocyte biology.

Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders.

M. Fey, A. Tobler, J. Schwaller, 1995, Blood.

The induction kinetics of Il-8 messenger RNA in HL60 cells demonstrate the participation of negative-acting gene(s).

M. Fey, A. Tobler, G. Niklaus, 1995, Leukemia research.

Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia

M. Fey, B. Dewald, T. Geiser, 1993 .

Principles of systemic therapy

M. Fey, S. Aebi, 2017 .

Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.

D. Böhlen, U. Studer, M. Fey, 1999, The Journal of urology.

Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.

U. Studer, M. Fey, D. Westermann, 2008, The Journal of urology.

Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer.

L. Mazzucchelli, U. Studer, M. Fey, 1993, European urology.

Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.

R. Stahel, M. Fey, A. Tobler, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal Analysis of Human Tumors with M27,6, a Highly Informative Polymorphic X Chromosomal Probe

M. Fey, A. Tobler, A. Zimmermann, 2013 .

Prevalence of the rhesus‐negative phenotype in caucasian patients with small‐cell lung cancer (SCLC)

M. Castiglione, M. Fey, M. Lind, 1992, International journal of cancer.

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of acute myeloblastic leukaemia (AML) in adult patients.

M. Fey, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.

U. Studer, M. Fey, G. Thalmann, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up.

M. Fey, M. Dreyling, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies

L. Guillou, M. Fey, S. Leyvraz, 2006, British Journal of Cancer.

Clonal loss of heterozygosity in microdissected Hodgkin and Reed-Sternberg cells.

M. Fey, M. Tinguely, J. Cajot, 1999, Journal of the National Cancer Institute.

BRIEF Clonal Loss of Heterozygosity in Microdissected Hodgkin and Reed-Sternberg Cells

M. Fey, M. Tinguely, A. Tobler, 1999 .

Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK).

R. Herrmann, M. Fey, B. van Hille, 1997, European journal of haematology.

ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients.

R. Greil, M. Fey, L. Jost, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.

C. Chastang, M. Fey, P. Fenaux, 1995, Leukemia & lymphoma.

CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16).

M. Fey, T. Pabst, D. Betts, 2005, Blood.

A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL).

Rolf Jaggi, Jörg Hager, Andreas Tobler, 2002, Blood.

Pleural tumors as sole primary manifestation of acute promyelocytic leukemia.

M. Fey, T. Pabst, B. Mueller, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The Multicenter Trial SAKK 37/95 of Cladribine, Cyclophosphamide and Prednisone in the Treatment of Chronic Lymphocytic Leukemias and Low-Grade Non-Hodgkin’s Lymphomas

M. Fey, G. Zulian, P. Ballabeni, 2006, Acta Haematologica.

Leukaemia and pregnancy.

M. Fey, D. Surbek, 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

The polymerase chain reaction: a new tool for the detection of minimal residual disease in haematological malignancies.

M. Fey, A. Tobler, A. Kulozik, 1991, European journal of cancer.

MTS1 expression and prognosis in acute myeloid leukemia

R. Herrmann, C. Rochlitz, M. Fey, 1997, Annals of Hematology.

Epstein-Barr virus-associated anaplastic large cell lymphoma in renal transplant patients.

M. Fey, K. Gatter, A. Tobler, 1992, American journal of clinical pathology.

Different p16INK4a and p14ARF Expression Patterns in Acute Myeloid Leukaemia and Normal Blood Leukocytes

M. Tschan, M. Fey, J. Cajot, 2001, Leukemia & lymphoma.

Linking the SUMO protease SENP5 to neutrophil differentiation of AML cells

B. Torbett, M. Tschan, M. Fey, 2015, Leukemia research reports.

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

M. Zwahlen, M. Egger, M. Schumacher, 2009, The Lancet.

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53.

G. Melino, M. Fey, V. de Laurenzi, 2001, Cell death and differentiation.

Inactivation of the hypermethylated in cancer 1 tumour suppressor--not just a question of promoter hypermethylation?

M. Tschan, M. Fey, C. Britschgi, 2010, Swiss medical weekly.

Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials).

H. Dombret, A. Vekhoff, S. Chevret, 2005 .

A PvuII restriction fragment length polymorphism of the glucose-6-phosphate dehydrogenase gene is an African-specific marker

T. Vulliamy, M. Fey, L. Luzzatto, 1990, Human Genetics.

HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation

B. Torbett, M. Tschan, M. Fey, 2008, British journal of haematology.

High-dose cytosine arabinoside therapy for refractory leukemia.

M. Fey, 1984, Blood.

Clonal X-inactivation analysis of human tumours using the human androgen receptor gene (HUMARA) polymorphism: a non-radioactive and semiquantitative strategy applicable to fresh and archival tissue.

M. Fey, P. Kopp, A. Tobler, 1997, Molecular and cellular probes.

High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.

M. Fey, A. Gratwohl, A. Tobler, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.

F. Cavalli, R. Herrmann, M. Fey, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group.

H. Dombret, S. Chevret, M. Fey, 2000, Leukemia.

Expression and regulation of G1 cell-cycle inhibitors (p16INK4A , p15INK4B, p18 INK4C, p19INK4D ) in human acute myeloid leukemia and normal myeloid cells

M. Fey, A. Tobler, H. Koeffler, 1997, Leukemia.

Inhibition of the miR-143/145 cluster attenuated neutrophil differentiation of APL cells.

M. Tschan, M. Fey, J. Batliner, 2012, Leukemia research.

analysis benefits for whom? results of a HOVON/SAKK donor versus no donor remission acute myeloid leukemia in young and middle aged adults: Myeloablative HLA-identical sibling stem cell transplantation in first

M. Fey, A. Gratwohl, B. Löwenberg, 2013 .

The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1

B. Torbett, T. Haferlach, M. Tschan, 2010, Leukemia.

A. Coates, J. Lindtner, M. Fey, 2004, Journal of Clinical Oncology.

CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation.

B. Torbett, M. Mancarelli, M. Tschan, 2011, Molecular immunology.

Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up.

M. Fey, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.

Augustin Ferrant, Bob Löwenberg, Alois Gratwohl, 2003, The New England journal of medicine.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, ESMO Open.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

E. Vellenga, M. Fey, M. Jongen‐Lavrencic, 2014, Leukemia.

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Augustin Ferrant, Alois Gratwohl, Matthias Theobald, 2007, Blood.

Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.

M A Boogaerts, A. Hagenbeek, E. Vellenga, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells.

M. Tschan, M. Fey, D. Aebersold, 2013, Biochemical and biophysical research communications.

P. Sonneveld, E. Vellenga, B. van der Holt, 2007, Annals of Hematology.

Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).

F. Cavalli, M. Fey, A. Gratwohl, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype

M. Fey, M. Bienz, T. Pabst, 2005, Clinical Cancer Research.

Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.

G. Margison, M. Fey, A. Ziemiecki, 1991, Cancer research.

status at diagnosis previously untreated acute myeloid leukemia (AML), in relation to MDR1 daunorubicin and cytarabine in the treatment of elderly patients with The value of the MDR1 reversal agent PSC-833 in addition to

E. Vellenga, M. Fey, G. Ossenkoppele, 2013 .

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.

P. Sonneveld, E. Vellenga, B. van der Holt, 2005, Blood.

The value of the MDR 1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia ( AML ) , in relation to MDR 1 status at diagnosis

E. Vellenga, M. Fey, P. Piccaluga, 2022 .

Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.

M. Bonetti, R. Gelber, A. Goldhirsch, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.

A. Goldhirsch, J. Collins, A. Coates, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

Bruce E. Torbett, Mario P. Tschan, B. Torbett, 2014, Scientific Reports.

PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity

B. Torbett, M. Tschan, M. Fey, 2008, Oncogene.

Epigallocatechin‐3‐gallate induces cell death in acute myeloid leukaemia cells and supports all‐trans retinoic acid‐induced neutrophil differentiation via death‐associated protein kinase 2

M. Tschan, M. Fey, A. Tobler, 2010, British journal of haematology.

Tumour heterogeneity and clonality--an old theme revisited.

M. Fey, A. Tobler, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of clonality in human tumors: a review.

M. Fey, J. Wainscoat, 1990, Cancer research.

Induction of Genes Mediating Interferon-dependent Extracellular Trap Formation during Neutrophil Differentiation*

R. Dummer, M. Fey, H. Simon, 2004, Journal of Biological Chemistry.

Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.

A. Baruchel, G. Leverger, S. Chevret, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.

J. Miguel, H. Dombret, A. Stamatoullas, 2000 .

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial

H. Dombret, A. Stamatoullas, E. Solary, 2000, British journal of haematology.

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia

H. Dombret, S. Chevret, M. Fey, 2000, Leukemia.

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

J. Miguel, H. Dombret, A. Stamatoullas, 1999, Blood.

Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

J. Forbes, M. Bonetti, R. Gelber, 2003, Journal of Clinical Oncology.

Molecular diagnosis of haematological neoplasms.

M. Fey, J. Wainscoat, 1988, Blood reviews.

Clonal analysis of a B-cell lymphoma with recurrent spontaneous remissions and evolution into chronic lymphocytic leukaemia.

B Borisch, M. Fey, A. Tobler, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia

M. Tschan, M. Fey, A. Tobler, 1999, Oncogene.

Tumor suppressor genes in myeloid differentiation and leukemogenesis.

M. Fey, C. Britschgi, 2009, Future oncology.

Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe.

M. Fey, A. Tobler, S. Nagel, 1994, Blood.

Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up.

M. Fey, M. Dreyling, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells

B. Torbett, M. Tschan, M. Fey, 2015, Journal of leukocyte biology.

Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22‐23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research

F. Cavalli, M. Ghielmini, L. Baldini, 2004, British journal of haematology.

Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure

M. Fey, A. Tobler, A. Rohr, 1996, Annals of Hematology.

Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis.

M. Tschan, M. Fey, U. Lass, 1999, Cancer research.

Clonal allele loss in gastrointestinal cancers.

M. Fey, S. Gendler, J. Wainscoat, 1989, British Journal of Cancer.

Allelotyping in B-Cell Chronic Lymphocytic Leukemia (B-CLL)

M. Fey, A. Tobler, U. Novak, 2004, Leukemia & lymphoma.

Microsatellite markers in leukaemia and lymphoma: comments on a timely topic.

M. Fey, 1997, Leukemia & lymphoma.

Somatic mutations detected by mini- and microsatellite DNA markers reveal clonal intratumor heterogeneity in gastrointestinal cancers.

M. Fey, A. Tobler, S. Nagel, 1995, Cancer research.

Studying clonal heterogeneity in human cancers.

M. Fey, A. Tobler, B. Borisch, 1993, Cancer research.

Up-regulation of p21WAF1 expression in myeloid cells is activated by the protein kinase C pathway.

M. Fey, A. Tobler, J. Schwaller, 1997, British Journal of Cancer.

Assessment of clonality in gastrointestinal cancer by DNA fingerprinting.

M. Fey, S. Thein, J. Wainscoat, 1988, The Journal of clinical investigation.

Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53

G. Melino, M. Fey, V. Laurenzi, 2001, Cell Death and Differentiation.

Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia.

G. Melino, M. Tschan, M. Fey, 2000, Biochemical and biophysical research communications.

Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours

M. Tschan, M. Fey, S. Aebi, 2000, International journal of cancer.

PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells.

B. Torbett, T. Haferlach, M. Tschan, 2012, Blood.

Expression of TCL1 in Hematologic Disorders

C. Croce, R. Dummer, M. Fey, 2001, Pathobiology.

Long term follow-up of factitious anaemia

M. Fey, Andreas Radvila, 1988, British medical journal.

What is the current treatment of PTLD after liver transplantation?

J. Dufour, M. Fey, 2006, Journal of hepatology.

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

M. Ghielmini, R. Stupp, M. Fey, 2004, Blood.

Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.

J. Bourhis, H. Dombret, S. Chevret, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.

M. Tschan, M. Fey, M. Gugger, 2017, Lung cancer.

Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study.

M. Ghielmini, M. Fey, A. Tobler, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Biology of Cancer

M. Fey, 2013 .

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

R. Gelber, A. Goldhirsch, J. Collins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of somatic mutations at human minisatellite loci in tumors and cell lines.

A. Jeffreys, J. Armour, M. Fey, 1989, Genomics.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93

J. Forbes, R. Gelber, A. Goldhirsch, 2009, Breast Cancer Research and Treatment.

Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer : Results of the International Breast Cancer Study Group ( IBCSG ) Trial

F. Cavalli, A. Goldhirsch, M. Castiglione, 2005 .

Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials.

M. Fey, S. Aebi, A. Tobler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.

R. Gelber, A. Goldhirsch, A. Coates, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence o f E ndocrine-Relate d F actors o n R esponse t o Perioperative C hemotherapy f or P atients W ith N ode- Negative B reast C ancer

R. Gelber, A. Coates, M. Castiglione‐Gertsch, 2001 .

Ovarian cancer. an institutional review of patterns of care, health insurance and prognosis.

E. Dreher, W. Hänggi, M. Fey, 2000, European journal of cancer.

Relationship Between Cleaved L-Selectin Levels and the Outcome of Acute Myeloid Leukemia

M. Fey, A. Tichelli, M. Extermann, 1998 .

Relationship between cleaved L-selectin levels and the outcome of acute myeloid leukemia.

M. Fey, A. Tichelli, M. Extermann, 1998, Blood.

Five putative drug resistance parameters (MDR1/P‐glycoprotein, MDR‐associated protein, glutathione‐S‐transferase, bcl‐2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias

R. Herrmann, M. Fey, A. Lohri, 1997 .

Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

F. Cavalli, A. Goldhirsch, M. Castiglione, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Cytostatic drug resistance: parallel assessment of glutathione‐based detoxifying enzymes, O 6 ‐alkylguanine‐DNA‐alkyltransferase and P‐glycoprotein in adult patients with leukaemia

G. Margison, M. Fey, A. Gratwohl, 1993, British journal of haematology.

Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology.

M. Tschan, M. Fey, M. Gugger, 2014, Future oncology.

MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma

M. Tschan, M. Fey, R. Jaggi, 2012, Oncogene.

MicroRNA-381 Represses ID1 and is Deregulated in Lung Adenocarcinoma

M. Tschan, M. Fey, R. Jaggi, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data

M. Egger, J. Bernhard, M. Fey, 2014, British Journal of Cancer.

DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function

M. Tschan, K. Helin, M. Fey, 2008, Oncogene.

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

H. Dombret, S. Chevret, B. Quesnel, 2006, Leukemia.

Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A)

M. Fey, H. Simon, S. Yousefi, 2008, Cell Death and Differentiation.

Detection of microsatellite markers in leukaemia using DNA from archival bone marrow smears

M. Fey, A. Tobler, T. Pabst, 1996, British journal of haematology.

Inhibition of damage-regulated autophagy modulator-1 (DRAM-1) impairs neutrophil differentiation of NB4 APL cells.

M. Tschan, M. Fey, Magali Humbert, 2012, Leukemia research.

BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation

B. Torbett, M. Tschan, M. Fey, 2012, Experimental Hematology & Oncology.

Deregulated expression of Kruppel-like factors in acute myeloid leukemia.

M. Tschan, M. Fey, A. Tobler, 2011, Leukemia research.

SIRT1 is downregulated during neutrophil differentiation of acute promyelocytic leukaemia cells

M. Tschan, M. Fey, C. Britschgi, 2009, British journal of haematology.

ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.

Daniel G Tenen, D. Tenen, M. Fey, 2004, Blood.

Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C. Buske, M. Fey, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[Adjuvant therapy for colon cancer].

M. Fey, 2000, Schweizerische medizinische Wochenschrift.

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

A. Hauschild, S. Ugurel, W. Stolz, 2001, British Journal of Cancer.

Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience

J. Miguel, J. Bourhis, H. Dombret, 2005, Leukemia.

Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance

R. Pieters, K. Sikora, W. Siegert, 1991, Journal of Cancer Research and Clinical Oncology.

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

F. Cavalli, R. Gelber, A. Goldhirsch, 1998, European journal of cancer.

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

M. Ghielmini, R. Stahel, M. Fey, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines

M. Delorenzi, M. Fey, T. Grob, 2006, British journal of haematology.

VI. DNA microarray technology. Principles and application to the analysis of malignant tumours (with special emphasis on lymphoma)

M. Fey, 2011 .

[Recombinant proteins as therapeutic compounds in clinical oncology].

M. Fey, 2011, Therapeutische Umschau. Revue therapeutique.

Overexpression of the p 73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia

M. Tschan, M. Fey, S. Aebi, 2005 .

Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia.

M. Tschan, M. Fey, S. Aebi, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting

M. Fey, S. Aebi, O. Gautschi, 2010, Supportive Care in Cancer.

The hDMP1 tumor suppressor is a new WT1 target in myeloid leukemias

B. Torbett, M. Tschan, M. Fey, 2008, Leukemia.

Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience

A. Vekhoff, S. Chevret, M. Fey, 2003, Leukemia.

Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial

J. Miguel, H. Dombret, A. Vekhoff, 2003, Leukemia.

Clinical Practice Guidelines Acute Myeloblastic Leukaemias and Myelodysplastic Syndromes in Adult Patients: Esmo Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up on Behalf of the Esmo Guidelines Working Group* Risk Assessment and Prognostic Factors

M. Fey, M. Dreyling, M Dreyling, 2022 .

Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.

R. Gelber, A. Goldhirsch, J. Collins, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

J. Forbes, M. Bonetti, R. Gelber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.

J. Forbes, R. Gelber, B. Gusterson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of drug resistance parameters in adult leukemia.

M. Fey, T. Cerny, M. Stadler, 1995, Leukemia & lymphoma.

Risk F actors f or L ocoregional R ecurrence A mong B reast Cancer P atients: R esults F rom I nternational B reast C ancer Study G roup T rials I T hrough V II

M. Bonetti, A. Goldhirsch, J. Collins, 2003 .

Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.

A. Lissoni, M. Fey, S. Leyvraz, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The actin‐binding protein CORO1A is a novel PU.1 (SPI1)‐ and CEBPA‐regulated gene with significantly lower expression in APL and CEBPA‐mutated AML patients

B. Torbett, G. Behre, M. Tschan, 2013, British Journal of Haematology.

Identifying B reast C ancer P atients a t H igh R isk f or Bone M etastases

F. Cavalli, M. Bonetti, R. Gelber, 2000 .

The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation.

B. Torbett, M. Tschan, M. Fey, 2016, Leukemia research.

Blocking the Autophagy Gene 5 (ATG5) Impairs ATRA-Induced Myeloid Differentiation, and ATG5 Is Downregulated in AML

M. Tschan, M. Fey, A. Tobler, 2008 .

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century

R. Gelber, A. Goldhirsch, J. Collins, 2009, Breast Cancer Research and Treatment.

Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).

F. Cavalli, A. Goldhirsch, C. Hürny, 1999, European journal of cancer.

Identifying breast cancer patients at high risk for bone metastases.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML‐RARα in APL

B. Torbett, T. Haferlach, G. Behre, 2014, Journal of Leukocyte Biology.

Induction of the autophagy-associated gene MAP1S via PU.1 supports APL differentiation.

B. Torbett, M. Tschan, M. Fey, 2014, Leukemia research.

Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation

K. Götze, M. Fey, W. Brugger, 2010 .

Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group [letter]

M. Fey, E. Wattel, B. Hecquet, 1994 .

Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group.

M. Fey, E. Wattel, B. Hecquet, 1994, Blood.

Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Interferon‐α‐2a with or without 13‐cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma

M. van Glabbeke, S. Fosså, M. Fey, 2004 .

UICC Manual of Clinical Oncology: O'Sullivan/UICC

B. O'Sullivan, J. Brierley, M. Fey, 2015 .

Frequent clonal loss of heterozygosity but scarcity of microsatellite instability at chromosomal breakpoint cluster regions in adult leukemias.

M. Fey, A. Tobler, J. Schwaller, 1996, Blood.

p73 Status in B-cell Chronic Lymphocytic Leukaemia

M. Fey, T. Grob, A. Tobler, 2004, Leukemia & lymphoma.

Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98.

M. Ghielmini, R. Stahel, M. Fey, 2009, Journal of Clinical Oncology.

Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.

M. van Glabbeke, S. Fosså, M. Fey, 2004, Cancer.

Pneumococcal vaccination in splenectomised cancer patients.

M. Fey, T. Pabst, K. Mühlemann, 2005, European journal of cancer.

Normal and malignant hematopoiesis.

M. Fey, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Inhibition of the arachidonic acid pathway prevents induction of IL‐8 mRNA by phorbol ester and changes the release of IL‐8 from HL 60 cells: Differential inhibition of induced expression of IL‐8, TNF‐α, IL‐1α, and IL‐1β

M. Fey, B. Dewald, A. Tobler, 1995 .

[Sentinel lymphadenectomy: an alternative to axillary lymphadenectomy in breast carcinoma].

E. Dreher, W. Hänggi, M. Fey, 1998, Schweizerische medizinische Wochenschrift.

Impact of the Human Genome Project on the clinical management of sporadic cancers.

M. Fey, 2002, The Lancet. Oncology.

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

K. Götze, M. Fey, W. Brugger, 2012, Leukemia.

Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.

A. Ganser, C. Chastang, M. Fey, 1993, Blood.

Colorectal Tumors Potential Indicators of Constitutive Drug Resistance in Human-Alkylguanine-DNA Alkyltransferase as 6 O Enzymes and Assessment of P-Glycoprotein , Glutathione-based Detoxifying

G. Margison, M. Fey, A. Ziemiecki, 2006 .

Cladribine (2‐CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia

M. Fey, D. Betticher, T. Cerny, 1997, British journal of haematology.

Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?

A. Hagenbeek, E. Vellenga, M. Fey, 1999, Bone Marrow Transplantation.

Somatic rearrangement of the tropomyosin-receptor-kinase (trk) oncogene is rare in gastrointestinal cancer.

M. Fey, S. Thein, 1988, British Journal of Cancer.

Immunogenotyping with antigen receptor gene probes as a diagnostic tool in childhood acute lymphoblastic leukaemia

É. Khandjian, M. Fey, A. Tobler, 1990, European journal of haematology.

Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)

R. Herrmann, C. Rochlitz, M. Fey, 1999, Leukemia.

Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters.

M. Fey, P. Kopp, A. Tobler, 1994, The Journal of clinical endocrinology and metabolism.

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.

A. Goldhirsch, J. Collins, A. Coates, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Frequent clonal loss of heterozygosity but scarcity of microsatellite instability at chromosomal breakpoint cluster regions in adult leukemias

M. Fey, A. Tobler, A. Tichelli, 1996 .

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

R. Gelber, A. Goldhirsch, J. Collins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Marriage risk of cancer research fellows

M. Fey, A. Tobler, 2011, The Lancet.

Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL).

G. Salles, M. Ghielmini, M. Fey, 2010 .

Single early palliative care intervention added to usual oncology care for patients with advanced cancer: A randomized controlled trial (SENS Trial)

D. Aujesky, M. Fey, D. Aebersold, 2021, Palliative medicine.

Pneumococcal vaccination in splenectomised cancer patients.

M. Fey, T. Pabst, K. Mühlemann, 2005, European journal of cancer.